Literature DB >> 21863049

Tumorigenesis: the origins of glioma.

Gemma K Alderton.   

Abstract

Entities:  

Year:  2011        PMID： 21863049     DOI： 10.1038/nrc3129

Source DB:  PubMed          Journal:  Nat Rev Cancer        ISSN： 1474-175X            Impact factor:   60.716


× No keyword cloud information.
  2 in total

1.  Mosaic analysis with double markers reveals tumor cell of origin in glioma.

Authors:  Chong Liu; Jonathan C Sage; Michael R Miller; Roel G W Verhaak; Simon Hippenmeyer; Hannes Vogel; Oded Foreman; Roderick T Bronson; Akiko Nishiyama; Liqun Luo; Hui Zong
Journal:  Cell       Date:  2011-07-07       Impact factor: 41.582

Review 2.  Targeting brain cancer: advances in the molecular pathology of malignant glioma and medulloblastoma.

Authors:  Jason T Huse; Eric C Holland
Journal:  Nat Rev Cancer       Date:  2010-05       Impact factor: 60.716
  2 in total
  7 in total

1.  Correlations of MUC15 overexpression with clinicopathological features and prognosis of glioma.

Authors:  Wen-Bing Yang; Cheng-Yan Li
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2014-04-08

Review 2.  LncRNAs and CircRNAs in cancer.

Authors:  Xin Yin; Huiran Lin; Lei Lin; Lei Miao; Jing He; Zhenjian Zhuo
Journal:  MedComm (2020)       Date:  2022-05-12

3.  Inhibitory activities of trichostatin a in U87 glioblastoma cells and tumorsphere-derived cells.

Authors:  Felipe de Almeida Sassi; Lílian Caesar; Mariane Jaeger; Carolina Nör; Ana Lucia Abujamra; Gilberto Schwartsmann; Caroline Brunetto de Farias; Algemir Lunardi Brunetto; Patrícia Luciana da Costa Lopez; Rafael Roesler
Journal:  J Mol Neurosci       Date:  2014-01-25       Impact factor: 3.444

4.  Hugl-1 inhibits glioma cell growth in intracranial model.

Authors:  Xuejiao Liu; Dong Lu; Peng Ma; Huaqiang Liu; Yuewen Cao; Ben Sang; Xianlong Zhu; Qiong Shi; Jinxia Hu; Rutong Yu; Xiuping Zhou
Journal:  J Neurooncol       Date:  2015-09-04       Impact factor: 4.130

5.  Type 5 phosphodiesterase regulates glioblastoma multiforme aggressiveness and clinical outcome.

Authors:  Valeriana Cesarini; Maurizio Martini; Lucia Ricci Vitiani; Giovanni Luca Gravina; Silvia Di Agostino; Grazia Graziani; Quintino Giorgio D'Alessandris; Roberto Pallini; Luigi M Larocca; Pellegrino Rossi; Emmanuele A Jannini; Susanna Dolci
Journal:  Oncotarget       Date:  2017-02-21

Review 6.  A critical evaluation of PI3K inhibition in Glioblastoma and Neuroblastoma therapy.

Authors:  Mike-Andrew Westhoff; Georg Karpel-Massler; Oliver Brühl; Stefanie Enzenmüller; Katia La Ferla-Brühl; Markus D Siegelin; Lisa Nonnenmacher; Klaus-Michael Debatin
Journal:  Mol Cell Ther       Date:  2014-10-27

7.  Epigenetic Modification and Differentiation Induction of Malignant Glioma Cells by Oligo-Fucoidan.

Authors:  Chien-Huang Liao; I-Chun Lai; Hui-Ching Kuo; Shuang-En Chuang; Hsin-Lun Lee; Jacqueline Whang-Peng; Chih-Jung Yao; Gi-Ming Lai
Journal:  Mar Drugs       Date:  2019-09-08       Impact factor: 5.118
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.